Skip to content
Biodatica
Start free

National Health Research Institutes, Taiwan

Kaohsiung City

OncologyPhase II
Compare Sign in to watch

What changed

Phase II trial registered: Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment

2w agoTrial registeredJul 2, 2026Source filing (opens the source filing in a new tab)

Momentum

78no change

Momentum 78 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,843 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Sep 1, 2025

    Hepatocellular Carcinoma (HCC) · NOT_YET_RECRUITING · sponsor: National Health Research Institutes, Taiwan · Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy

    ClinicalTrials.gov · NCT07151326 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    May 10, 2025

    Solid Tumor Cancer · RECRUITING · sponsor: China Medical University Hospital · Imatinib and Trametinib for KRAS-mutated Solid Tumor

    ClinicalTrials.gov · NCT06962254 (opens the source filing in a new tab)

  3. Trial

    Study registered

    Dec 29, 2022

    Primary Malignant Brain Tumors · RECRUITING · sponsor: National Health Research Institutes, Taiwan · A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma

    ClinicalTrials.gov · NCT05622409 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Jul 1, 2022

    Advanced Biliary Tract Cancer · ACTIVE_NOT_RECRUITING · sponsor: National Health Research Institutes, Taiwan · Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment

    ClinicalTrials.gov · NCT05170438 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Feb 22, 2021

    Primary Central Nervous System Lymphoma (PCNSL) · ACTIVE_NOT_RECRUITING · sponsor: National Health Research Institutes, Taiwan · Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.

    ClinicalTrials.gov · NCT04688151 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources